BerGenBio dispute resolved February 28. 2019 BerGenBio ASA (OSE:BGBIO) has informed that the six months long arbitration with Rigel regarding the licensing agreement has been resolved. This news and the content of the settlement is very positive for the Bergen based...

Vaccibody to present 4 poster during AACR Vaccibody AS has been accepted for an impressive 4 poster presentations at the annual meeting in the American Association for Cancer Research in April 2019. Two of the papers demonstrates the progress made with the unique...

Vaccibody secures NOK 230 million (EUR 23,6 million) The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used to conduct a Phase IIa clinical study combining Vaccibody’s...